ReviewCurrent oncology reports2021
Immunotherapy in Cervical Cancer.
Review in Current oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 104 citations in OpenAlex.
- Ivonescimab combined with chemotherapy for the treatment of metastatic cervical cancer: A case report and literature review.Human vaccines & immunotherapeutics · 2026Review
- GATA1 knockdown enhances CD8Journal of molecular histology · 2026Article
- Innovative peptide-loaded hybrid membrane nanovaccine enables precise personalized immunotherapy for HPV-related cervical diseases.Signal transduction and targeted therapy · 2026Article
- Analysis of Quality, Reliability, and Content of Cervical Cancer-Related Chinese Videos on TikTok.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026Article
- Current evidence and emerging approaches in immunotherapy for gynecological cancers.Discover oncology · 2026Review
- Nomogram Prediction Model and Prognostic Comparison of Cervical Clear Cell Carcinoma and Cervical Endometrioid Adenocarcinoma: A SEER Database Study.Cancer medicine · 2026Article
- Integrated single-cell and bulk RNA sequencing unravels neutrophil heterogeneity and validates SPP1 as a prognostic biomarker in cervical cancer.BMC cancer · 2026Article
- Association between pelvic bone marrow dosimetry and acute hematologic toxicity during concurrent chemoradiotherapy for gynecologic malignancies.Journal of radiation research · 2026Article
- AGRN activates GPX4 via the Wnt/beta-catenin signaling pathway to suppress ferroptosis in cervical cancer cells.Briefings in functional genomics · 2026Article
- MicroRNA-628-5p Regulates Proliferation, Apoptosis and Invasion in Hela Cells.Iranian journal of biotechnology · 2026Article
- Bulk and single cell RNA sequencing data reveal lactylation-related gene signatures for prognosis and immunity in cervical cancer.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Article
- Prognostic impact of HLA-G expression in cervical squamous cell carcinoma: correlation with PD-L1 and CD8-positive tumor infiltrating lymphocytes.Frontiers in immunology · 2026Article
- Review
- TM4SF1 as a Prognostic Biomarker and Therapeutic Target in Cervical Cancer.Current medical science · 2025Article
- LAG3 as a Tumor Suppressor and Immune Regulator in Cervical Cancer: From Functional Validation to Therapeutic Strategy.Cancer medicine · 2025Article
- Bioinformatics-based identification of key genes for Olaparib resistance in breast cancer: prognostic implications and therapeutic relevance.Discover oncology · 2025Article
- Piezo1 regulates actin cytoskeleton remodeling to drive EMT in cervical cancer through the RhoA/ROCK1/PIP2 signaling pathway.Discover oncology · 2025Article
- Nanovaccines against Cervical Cancer: Reliable Strategies to Circumvent Limitations of Traditional Therapeutic Vaccines.Advanced pharmaceutical bulletin · 2025Review
- N-glycosylation of GSTO1 promotes cervical cancer migration and invasion through JAK/STAT3 pathway activation.Functional & integrative genomics · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review aims to summarize the current immunotherapy studies and the potential targeted therapies showing promise in the treatment of cervical cancer. RECENT
findingsThere are promising ongoing monotherapy and combination therapy trials using different immune checkpoint inhibitors, poly adenosine diphosphate ribose polymerase inhibitors, tumor angiogenesis inhibitors (i.e., bevacizumab), antibody-drug conjugates, therapeutic vaccines, and tumor-infiltrating T lymphocytes (adoptive immunotherapy). Some of these novel modalities are also being evaluated in combination with standard platinum-based chemotherapy regimen. At this time, pembrolizumab is approved for the treatment of relapsed or metastatic programmed death ligand 1 (PD-L1) positive cervical cancer after frontline chemotherapy treatment. Multiple novel therapeutic modalities are emerging as safe and effective for the treatment of cervical cancer patients. Development and participation in investigative treatments can provide benefit and improve outcomes in cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.